New prognostic model predicts survival in advanced prostate cancer

(Medical Xpress)—For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.

But a good prognostic tool has been lacking in this setting, particularly since a new called cabazitaxel as been approved by the U.S. Food and Drug Administration as another line of treatment.

Now researchers at the Duke Cancer Institute have developed a tool for doctors to forecast the potential survival of individual , enabling them to better and rapidly assess whether to try additional rounds of treatment or seek clinical trials.

The findings are published online in the Journal of the National Cancer Institute.

"Several new treatments have been developed in recent years that prolong life for men with metastatic ," said Susan Halabi, PhD, professor of biostatistics and bioinformatic at Duke and lead author of the study. "As a result, it's increasingly important to provide a clear prognostic picture that can help guide both doctors and patients to the best options."

In their study, Halabi and colleagues developed and validated the new prognostic tool using two different clinical trials of prostate cancer patients whose cancer returned after they had undergone a regimen of docetaxel, the standard first-round chemotherapy that is used after hormone treatments have been ineffective.

The researcher's approach provides an understanding of the complex interactions between the host, the tumor factors and clinical outcomes.

By plugging in 17 variables – including pain intensity, measurable disease, race, age, body mass index and others - the researchers homed in certain key factors that were relevant to overall survival.

Of the 17 variables, nine were determined to be predictive of survival: how a patient's physical performance is rated on a scale of 0-2; the length of time since the first chemotherapy ended; how extensive the disease is; whether the disease has spread to the liver, lungs or other organs; how much pain the patient is experiencing; the duration of hormone use; and levels of hemoglobin, prostate specific antigen and alkaline phosphatase.

Two of those factors had not previously been used in prognostic models - the duration of hormone therapy and the amount of time since the first-round docetaxel treatment.

"Our findings provide a that relies on information tha is routinely collected in clinical practice and should be readily available," Halabi said. "For patients with who are appropriate candidates for second-line chemotherapy, this model can be helpful for guiding care. It could also be used during to assign patients in risk groups based on measurable criteria."

Related Stories

Recommended for you

Spicy treatment the answer to aggressive cancer?

date Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.